CTI BioPharma Corp news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

CTIC 0.504 -0.022 (-4.20%)
price chart
CTI BioPharma Corp. (NASDAQ:CTIC) - Stock Review
CTI BioPharma Corp. (NASDAQ:CTIC) last reported quarterly EPS of $-0.13 for the period ending 2015-12-31. Before the earnings report, analysts contributing to the Zacks Research consensus were expecting EPS for the quarter of $-0.18.
Top Stories: CTI BioPharma Corp. (NASDAQ:CTIC), Occidental Petroleum ...  Benchmark Monitor
Trending Stocks: Infinera Corporation (NASDAQ:INFN), CTI BioPharma Corp ...  Stock Transcript
Why CTI BioPharma Corp. Came Crashing Down Today
What: Shares of CTI BioPharma (NASDAQ:CTIC), a small-cap biotech focused on the development of medicines to treat cancer, tumbled as much as 32% after the company announced a convertible preferred stock offering.
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock  PR Newswire (press release)
Biotech Beat: CTI BioPharma Corp (CTIC), ZIOPHARM Oncology Inc. (ZIOP) and ...  Smarter Analyst
CTI BioPharma Corp (NASDAQ:CTIC) Making A Comeback
Shareholders of CTI Biopharma Corp (NASDAQ:CTIC) were hit with some bad news earlier this month. CTIC received an oral communication from the FDA followed by a letter notifying the company that the company's IND for pacritinib has been placed on full ...
FDA Scraps CTI BioPharma Corp Application For Pacritinib
The FDA has announced that CTI BioPhrama Corp's (NASDAQ:CTIC) Investigational New Drug (IND) application for pacritinib is put to a complete stop.
Robbins Arroyo LLP: CTI Biopharma Corp. (CTIC) Misled Shareholders According ...  Business Wire (press release)
Partial Clinical Hold Hits CTI BioPharma Corp
CTI BioPharma Corp. (NASDAQ:CTIC) has announced that it has put its clinical studies for pacritinib on hold, after receiving a letter from the US Food and Drug Administration (FDA) on February 4, 2016.
Bears of the Day: Analysts Raise Red Flags on CTI BioPharma Corp (CTIC) and ...  Smarter Analyst
Analyst Downgrades: Walt Disney Co, CTI BioPharma Corp, and ARM Holdings plc  Schaeffers Research (blog)
CTI BioPharma Corp (CTIC) Jumps 5.17% on April 20
CTI BioPharma Corp (CTIC) was among the biggest gainers on the Russell 2000 for Wednesday April 20 as the stock popped 5.17% to $0.57, representing a gain of $0.028 per share.
Healthcare Stocks Alert: CTI BioPharma Corp (CTIC), UnitedHealth Group Inc (UNH)  News Oracle
Biotech Companies To Look Out For: CTI BioPharma (CTIC), Pacific Biosciences ...  Zergwatch
Why CTI BioPharma Corp Shares Are Falling Today
What: Shares of CTI BioPharma (NASDAQ:CTIC), a small-cap biopharmaceutical company focused on creating products that treat blood-related cancers, were down more than 20% at one point in early trading today after the company announced the pricing ...
James Bianco Unloaded 260000 shares of CTI BioPharma Corp (NASDAQ:CTIC) in ...  OctaFinance.com
Company Update (NASDAQ:CTIC): CTI BioPharma Corp Presents Preclinical Data of ...
CTI BioPharma Corp (NASDAQ:CTIC) announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis and acute myeloid ...
Stock's Move to Focus: Cerus Corporation (NASDAQ:CERS) , CTI BioPharma ...  Street Updates
CTI BioPharma Shares Rise 7% on Pacritinib Potential to Eradicate Therapy ...  Sonoran Weekly Review
CTI BioPharma Corp (CTIC) Jumps 5.01% on April 13
CTI BioPharma Corp (CTIC) was among the biggest gainers on the Russell 2000 for Wednesday April 13 as the stock popped 5.01% to $0.52, representing a gain of $0.0248 per share.
CTI BioPharma Corp. (NASDAQ:CTIC) Reported Comprehensive Income Of $-6.952 ...  Stocks Daily
Traders Attention Alert: Cytori Therapeutics Inc (NASDAQ:CYTX) , CTI ...  Street Updates
SHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of ...
NEW YORK, April 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp. securities (NASDAQ:CTIC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in ...